|Bid||612.61 x 800|
|Ask||614.99 x 800|
|Day's Range||602.52 - 613.15|
|52 Week Range||536.08 - 747.42|
|Beta (5Y Monthly)||0.21|
|PE Ratio (TTM)||9.80|
|Earnings Date||Feb 03, 2022 - Feb 07, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||702.05|
Mega-blockbuster Dupixent was just given the FDA's green light to treat patients with a chronic, progressive inflammatory disease.
Regeneron (REGN) closed at $612.49 in the latest trading session, marking a +0.84% move from the prior day.
Intellia Therapeutics Inc (NASDAQ: NTLA) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) announced additional interim data from the Phase 1 study of NTLA-2001, in vivo genome editing candidate for transthyretin (ATTR) amyloidosis. Intellia had said that at the highest dose level (1.0mg/kg), six patients had shown a 93% mean reduction in the toxic protein. In the new data, three patients reached the nine-month follow-up point and maintained that level of TTR reduction. Related: Intellia Shares U